Lenalidomide, Adriamycin, Dexamethasone (RAD) followed by risk-adjusted transplant is a novel and very effective induction regimen in newly diagnosed multiple myeloma

Knop, S. and Langer, C. and Engelhardt, M. and Muegge, L-O and Roesler, W. and Reichle, A. and Roellig, C. and Hertenstein, B. and Gramatzki, M. and Bassermann, F. and Ostermann, H. and Sturm, I and Ringhoffer, M. and Schaefer-Eckart, K. and Falk, K. and Liebert, A. and Einsele, H. and Bargou, R. (2013) Lenalidomide, Adriamycin, Dexamethasone (RAD) followed by risk-adjusted transplant is a novel and very effective induction regimen in newly diagnosed multiple myeloma. ONKOLOGIE, 36 (Suppl7). p. 39. ISSN 0378-584X, 1423-0240

Full text not available from this repository.

Item Type:	Article
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User:	Petra Gürster
Date Deposited:	19 Jun 2020 06:10
Last Modified:	19 Jun 2020 06:10
URI:	https://pred.uni-regensburg.de/id/eprint/15896

Actions (login required)

View Item